These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 31093955

  • 1. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
    Mazarico I, Capel I, Giménez-Palop O, Albert L, Berges I, Luchtenberg F, García Y, Fernández-Morales LA, De Pedro VJ, Caixàs A, Rigla M.
    J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
    [Abstract] [Full Text] [Related]

  • 2. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y.
    JAMA Oncol; 2019 Mar 01; 5(3):376-383. PubMed ID: 30589930
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
    Presotto EM, Rastrelli G, Desideri I, Scotti V, Gunnella S, Pimpinelli N, Vaccher E, Bearz A, Di Costanzo F, Bruggia M, Mini E, Maggi M, Peri A.
    J Endocrinol Invest; 2020 Mar 01; 43(3):337-345. PubMed ID: 31542865
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database.
    Garon-Czmil J, Petitpain N, Rouby F, Sassier M, Babai S, Yelehe-Okouma M, Weryha G, Klein M, Gillet P.
    Fundam Clin Pharmacol; 2019 Apr 01; 33(2):241-249. PubMed ID: 30308083
    [Abstract] [Full Text] [Related]

  • 7. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
    Peiró I, Palmero R, Iglesias P, Díez JJ, Simó-Servat A, Marín JA, Jiménez L, Domingo-Domenech E, Mancho-Fora N, Nadal E, Villabona C.
    Endocrine; 2019 Jun 01; 64(3):605-613. PubMed ID: 30805887
    [Abstract] [Full Text] [Related]

  • 8. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
    Yano S, Ashida K, Nagata H, Ohe K, Wada N, Takeichi Y, Hanada Y, Ibayashi Y, Wang L, Sakamoto S, Sakamoto R, Uchi H, Shiratsuchi M, Furue M, Nomura M, Ogawa Y.
    BMC Endocr Disord; 2018 Jun 08; 18(1):36. PubMed ID: 29884162
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
    Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, Uraki S, Takeshima K, Furukawa Y, Morita S, Yamamoto Y, Yamashita S, Katsuda M, Hayata A, Akamatsu H, Jinnin M, Hara I, Yamaue H, Akamizu T.
    Cancer Sci; 2020 May 08; 111(5):1468-1477. PubMed ID: 32086984
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N.
    BMC Cancer; 2019 Oct 21; 19(1):974. PubMed ID: 31638948
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
    Guaraldi F, La Selva R, Samà MT, D'Angelo V, Gori D, Fava P, Fierro MT, Savoia P, Arvat E.
    J Endocrinol Invest; 2018 May 21; 41(5):549-556. PubMed ID: 29043574
    [Abstract] [Full Text] [Related]

  • 16. Thyroid disorders induced by checkpoint inhibitors.
    Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A.
    Rev Endocr Metab Disord; 2018 Dec 21; 19(4):325-333. PubMed ID: 30242549
    [Abstract] [Full Text] [Related]

  • 17. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
    Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S.
    Eur J Cancer; 2018 Jun 21; 96():91-104. PubMed ID: 29698933
    [Abstract] [Full Text] [Related]

  • 18. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
    Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M.
    J Clin Endocrinol Metab; 2017 Aug 01; 102(8):2770-2780. PubMed ID: 28609832
    [Abstract] [Full Text] [Related]

  • 19. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A, Kottschade L, Ryder M.
    Thyroid; 2020 Feb 01; 30(2):177-184. PubMed ID: 31813343
    [Abstract] [Full Text] [Related]

  • 20. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
    Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM.
    J Clin Endocrinol Metab; 2021 Aug 18; 106(9):e3704-e3713. PubMed ID: 33878162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.